

Synergistic effects of Iranian seaweed compounds for anticandidal properties and optimization by Response Surface Methodology

Taheri A.^{1*}

Received: October 2014

Accepted: November 2018

Abstract

An optimization procedure was applied to investigate the anticandidal property of four different Iranian seaweed extract compositions. Response Surface Methodology (RSM) with the four levels- three-factor Box-Behnken design, including *Gracilaria arquata* concentration (X_1), *Nizimudidnia zanardini* concentration (X_2), *Cystoceria indica* concentration (X_3) and *Padina australis* concentration (X_4), was used to screen for anticandidal property screening. Multiple regression analysis of data showed that the coefficient determination (R^2) was appropriate for the second-order model. The anticandidal property of the seaweed extract composition of 10 mg ml⁻¹ *G. arquata* extract, 5 mg ml⁻¹ *N. zanardini* extract, 4.5 mg ml⁻¹ *C. indica* extract and 2 mg ml⁻¹ *P. australis* extract was found to be optimal. Under the optimized composition, the *Candida albicans* growth inhibition zone was 26.23 mm. The experimental yield was well matched with the predicted yield.

Keywords: Anticandidal property, Response Surface Methodology (RSM), Seaweed extract, Box-Behnken design, *Candida albicans*

1-Fisheries Department, Faculty of Marine Sciences, Chabahar Maritime University, Chabahar, Iran, P.O.BOX. 99717- 56499.

*Corresponding author's Email: taherienator@gmail.com

Introduction

In the past three decades, fungal infections have increased due to the rising immunocompromised population (Black and Baden, 2007; Anaissie, 2008; Meunier and Lukan, 2008). *Candida albicans* (*C. albicans*) is the main commensal fungus living in the human vaginal canal, oral cavity, and gastrointestinal tract (Xu *et al.*, 1999). Due to the delay in the early diagnosis of fungal infection and deficit available antifungal drugs, the antifungal resistance is the main problem (Cannon *et al.*, 2007). Developing drug resistance is an old phenomenon. Toxic environmental stresses are obligate Microorganisms responding for millennia (Wright, 2007). Thus *candidiasis* remains a significant social and clinical problem (Kustos *et al.*, 2006). In recent years, there have been increasing efforts to find new antifungal compositions.

Recently, finding new antifungal drugs from plants has been interested due to the resistant strains and presence a few antifungal classes (Mishra *et al.*, 2007; Peres *et al.*, 2010). In more recent years, seaweed research has been increased to find new and effective medicines from natural sources (Kumar *et al.*, 2013). Many seaweeds natural products are being used, and different antibacterial and antifungal compounds have been reported from algal extracts (Guedes *et al.*, 2012).

Drug synergism is a recently reported novel idea (Silverman and Holladay, 2014). The antimicrobial medicinal plants that show synergism with antimicrobial medicines is essential

source of antimicrobial compounds for the use in combination therapies (Rakholiya *et al.*, 2013). These compounds may have no strong antibacterial properties, but may synergize with other drugs (Pyun and Shin, 2006; Ushimaru *et al.*, 2012). Combining antifungal drugs is increasingly thought of as a useful approach (Marr *et al.*, 2004; Sobel, 2004); more significant antimicrobial effect than the individual drug effect and possible smaller doses need than with monotherapy are the potential benefits, thus resulting in maximizing the spectrum of antifungal coverage (Sobel, 2004).

This study was conducted to optimize the anticandidal properties of compositions of four different seaweed extracts from Chabahar coast (Iran) using RSM to evaluate the growth inhibition of *C. albicans*.

Material and methods

Algae were collected from the beach of Chabahar (Iran) at a latitude of 25° 16' N and longitude of 60° 39' E during the low tide. After washing with distilled water, algae was dried in an oven at 45 °C for 3 h and crushed in a lab blender (Guedes *et al.*, 2012). 125 g of dried samples macerated in 250 ml of ethanol. The extract was filtered and treated in a Rota evaporator at 40 °C. The weight of the dried extract was 4.58 g.

Pure cultures of *C. albicans* procured from the Persian Type Culture Collection (PTCC), Tehran, Iran. First, SDA broth was prepared, inoculated, and incubated at 25 °C. Then, the

antifungal activity of seaweed extracts evaluated with a disc diffusion assay by loading 15 µg/ml of the extract on to the blank disk. Nystatin (Padtan teb, 100 units) used as a positive control.

Minimum inhibition concentrations (MIC) of the seaweed extracts evaluated according to the reference method (Standards, 2002), with some modifications. Briefly, The *C. albicans* was cultured in RPMI 1640 broth medium (5.0×10^2 to 2.5×10^3 cells per ml). Before adjusting the inoculum, 0.1 ml of the various anticandidal concentrations were added to the test tubes based on the ranges mentioned in Table 1 for each algal extract, 0.9 ml of which was placed in each tube in the dilution series and mixed. The tubes incubated at 35°C for 48 h. Microscope used in order to yeast cells number counting. The lowest concentration of

the extracts (colonies by $\geq 99.99\%$ compared to the control) was taken as the minimum fungicidal concentration (MFC) (Chudzik *et al.*, 2013).

To determine the best combination of seaweed extracts by enhanced anticandidal properties, a four-variable, three-level Box-Behnken design (BBD) was used. The four independent variable sets were concentrations of *G. arquata* extract (mg ml⁻¹, X₁), *Nizimudidnia zanardini* extract (mg ml⁻¹, X₂), *Cystoceria indica* extract (mg ml⁻¹, X₃) and *Padina australis* extract (mg ml⁻¹, X₄) (Table 1). The response was the growth inhibition zone. The following equation performed for the experimental data after regression analysis:

$$Y = \alpha_0 + \sum_{i=1}^4 \alpha_i X_i + \sum_{i=1}^4 \alpha_{ii} X_i^2 + \sum_{i=1}^3 \sum_{j=i+1}^4 \alpha_{ij} X_i X_j$$

Table 1: Independent variables and their levels used in the response surface design.

Independent variables	Factor level		
	-1	0	+1
X ₁ concentrations of <i>Gracilaria arquata</i> extract (mg ml ⁻¹)	4	7	10
X ₂ concentrations of <i>Nizimudidnia zanardini</i> extract (mg ml ⁻¹)	2.5	5	7.5
X ₃ concentrations of <i>Cystoceria indica</i> extract (mg ml ⁻¹)	2.5	5	7.5
X ₄ concentrations of <i>Padina australis</i> extract (mg ml ⁻¹)	1	2	3

Where Y is offset term, α_0 is a constant, α_i , α_{ii} and α_{ij} are regression coefficients and X_i and X_j are the levels of the independent variables. The range of independent variables and their levels are presented in Table 1, obtained of preliminary experiments. Design-Expert software (7.0.0 trial, Stat-Ease Inc., Minneapolis, MN, USA) used to analysis of the experimental design. The usefulness of the design evaluated by use of different random

combinations of parameters optimized design.

Results

A summary of the anticandidal activity of seaweed extracts against *C. albicans* is shown in Table 2. The ethanolic extract from all species of seaweeds was active against the yeast *C. albicans*. The extract of *Padina australis*, *N. zanardini*, and *G. arquata* showed significant inhibition zone of greater

than 20 mm diameter (24 ± 0.9 , 23 ± 0.0 and 21 ± 0.7 mm, respectively). The MIC and MFC values of algal extracts against *C. albicans* are summarized in Table 2. The least MIC and MFC values were recorded for *P.*

australis crude extract as 1.25 and 1.7, respectively. The maximum concentration of MIC and MFC values was recorded for the crude extract of *Gracilaria arquata*.

Table 2: Inhibitory activity of different Seaweed extracts and Nystatin against *Candida* sp. Individually.

species	Inhibitory activity against <i>Candida albicans</i>		
	Inhibition zone (mm)	MIC (mg ml ⁻¹)	MFC (mg ml ⁻¹)
<i>Gracilaria arquata</i>	21 ± 0.7	7.12	8.2
<i>Nizimudidnia zanardini</i>	23 ± 0.0	4.75	5.25
<i>Cystoceria indica</i>	19 ± 0.6	5	6
<i>Padina australis</i>	24 ± 0.9	1.25	1.7
Nystatin	26 ± 0.1	25 (µg ml ⁻¹)	30 (µg ml ⁻¹)

The four individual parameters were optimized in the Box–Behnken design (4^3 factorial) using 29 design experiments (Table 3). The mean values of the responses (*Candida* sp. growth inhibition zone) obtained from the different combinations of seaweed extracts are summarized in Table 4. The

application of RSM yields the below regression equation:

$$Y = -18.35972 + 4.22778X_1 + 2.97X_2 + 3.23333X_3 + 8.95833X_4 - 0.11X_1X_2 - 0.14X_1X_3 - 0.18333X_1X_4 + 0.208X_2X_3 + 0.43X_2X_4 - 0.16X_3X_4 - 0.13472X_1^2 - 0.368X_2^2 - 0.284X_3^2 - 2.1625X_4^2$$

Table 3: Experimental design used in RSM studies by using four independent variables with five center points showing the observed Inhibition Zone of *Candida albicans* growth.

Run No.	Coded levels of variable				Inhibition Zone (mm)
	X ₁	X ₂	X ₃	X ₄	
1	-1	-1	0	0	18.2
2	1	-1	0	0	24
3	-1	1	0	0	21.7
4	1	1	0	0	24.2
5	0	0	-1	-1	21.3
6	0	0	1	-1	21.6
7	0	0	-1	1	22.4
8	0	0	1	1	21.1
9	-1	0	0	-1	17.8
10	1	0	0	-1	24.4
11	-1	0	0	1	20.5
12	1	0	0	1	24.9
13	0	-1	-1	0	20.5
14	0	1	-1	0	20.5
15	0	-1	1	0	19.3
16	0	1	1	0	24.5
17	-1	0	-1	0	18.5
18	1	0	-1	0	24

Table 3 continued:

19	-1	0	1	0	21.7
20	1	0	1	0	23
21	0	-1	0	-1	20.3
22	0	1	0	-1	20
23	0	-1	0	1	18.5
24	0	1	0	1	22.5
25	0	0	0	0	25.9
26	0	0	0	0	25
27	0	0	0	0	24.4
28	0	0	0	0	25.7
29	0	0	0	0	25

Based on the ANOVA of the regression, the model was significant. A high F-value (16.32) and a low P-value ($p < 0.0001$) was seen (table 4). Correlation coefficient (R^2) value was 0.9423. The value of the adjusted determination coefficient was 0.8845

and coefficient of variation was a low 3.74%. The statistical analysis has a high significant value ($p < 0.0001$), testifying the fitness of the model for the growth inhibition zone. F-value was non significant ($p < 0.2288$) for the lack of fit.

Table 4: ANOVA results of growth inhibition zone of *Candida albicans* as affected by different concentrations of seaweed extracts during an optimization experiment.

	Sum of Squares	df	Mean Square	F Value	P Value
Model	156.49	14	11.18	16.32	<0.0001
Linear					
<i>A-G. arcuata</i>	56.77	1	56.77	82.88	<0.0001
<i>B-N. zanardini</i>	13.23	1	13.23	19.32	0.0006
<i>C-C. indica</i>	1.33	1	1.33	1.95	0.1847
<i>D-P. australis</i>	1.69	1	1.69	2.46	0.1388
Interaction					
AB	2.72	1	2.72	3.97	0.0660
AC	4.41	1	4.41	6.44	0.0237
AD	1.21	1	1.21	1.77	0.2051
BC	6.76	1	6.76	9.87	0.0072
BD	4.62	1	4.62	6.75	0.0211
CD	0.64	1	0.64	0.93	0.3501
Quadratic					
A ²	9.54	1	9.54	13.92	0.0022
B ²	34.31	1	34.31	50.10	<0.0001
C ²	20.44	1	20.44	29.84	<0.0001
D ²	30.33	1	30.33	44.29	<0.0001
Residual	9.59	14	0.68		
Lack of Fit	8.13	10	0.81	2.23	0.2288
Pure Error	1.46	4	0.37		
Cor Total	166.08	28			

Residual values distribution in the normal probability plot (Fig.1a) forms a straight line by a normal distribution of residual values on both sides. Further,

the observed values was compared with adequate predicted values. The parity plot (Fig.1b) was at an acceptable level.




Figure 1: Normal plot of residual and relationship between the observed and predicted values.

The main and interactive effects of the independent variables on the dependent one illustrated by the 3D response surface plots (Fig. 2a-f). Fig. 2a, b and c shows the effects of *G. arquata* concentration (X_1) with each of the three other factors on the inhibition of *C. albicans* growth. Based on the Fig. 1a, b and c, it implies that the *G. arquata* concentration is more significant than the other variables. In all cases there was a clear optimal concentration of *G. arquata* that peaked at 10 mg ml^{-1} . Fig. 2a, d and e show the effects of *N. zanardini* concentration (X_2) with each of the three other factors on the inhibition of of growth of *Candida* sp.. In all situations, the

inhibition zone increased with increasing *N. zanardini* concentration from 3.8 to 6.3 mg/ml , while less than 3.5 and more than 6.5 mg ml^{-1} appeared to be disadvantaged regarding the inhibition of the growth, which indicated that the *N. zanardini* concentration has remarkable effects on the response. The effects of *C. indica* concentration (X_3) interaction with each of the other factors on the inhibition zone are shown in Fig. 1b, d and e. Higher concentration resulted in higher inhibition. The inhibition zone of *C. albicans* growth increased by increasing the concentration from 3.6 to 6.3 mg ml^{-1} , and after that decreased.




Figure 2: Response surface plots of the effect of seaweed extract concentrations and their mutual interactions on the Inhibition of *Candida albicans* growth.

Discussion

In recent years, fungal infections are an increasing health problem, ranging from external to deeply disseminated (Duraipandiyar and Ignacimuthu, 2011). Seaweeds can produce a different kind of secondary metabolites

and is a source of bioactive metabolites. Compounds with cytotoxic and antimicrobial activities have been reported from a range of marine algae (Yuan *et al.*, 2005; Bansemir *et al.*, 2006; Chew *et al.*, 2008).

In this study, inhibition zones of *C. albicans* growth were used as a signal of antimicrobial activity. However, zone inhibition diameters varied according to the kind of seaweed extracts; but three different seaweed extracts showed an inhibition zone of more than 20 mm. This inhibition zone diameter showed the higher activity of the extracts against the yeast. This high activity may be due to the presence of bioactive metabolites soluble in ethanol (Tuney *et al.*, 2006).

Based on past research, the anticandidal activity of the marine algae, *Asparagopsis armata*, (inhibition zone [IZ] of 53.2 mm), was evaluated (Salvador *et al.*, 2007). Also the anticandidal activity of *U. lactuca* (IZ: 5.2–23.2 mm), *U. fasciata* (IZ: 6 mm), *E. compressa* (IZ: 10 mm), *P. capillacea* (IZ: 15.4 mm), *P. pavonica* (IZ: 15.4 mm) and *Ulva rigida* (IZ: 12 mm) was reported (Ertürk and Tas, 2011; Shobier *et al.*, 2016). Based on the literature, antifungal effects against *C. albicans* was reported for chloroform and ethyl acetate extracts of brown algae (ranged from 9 to 25 mm), but *U. lactuca* extracts showed no activity (Mhadhebi *et al.*, 2012; Guedes *et al.*, 2012). The results of the present study were better than most of the above-mentioned research as the inhibition zone was more than 20 mm.

Shobier *et al.* (2016), reported the MIC value of *U. lactuca* (8–16 $\mu\text{g ml}^{-1}$) and *U. fasciata* (128 $\mu\text{g ml}^{-1}$). The chloroform extract of *P. gymnospora* showed MIC at 16 $\mu\text{g ml}^{-1}$ against *Candida sp.* (Guedes *et al.*, 2012). Ertürk and Tas (2011) reported more

than 10 $\mu\text{g ml}^{-1}$ MIC for *U. rigida* extracts against *C. albicans*. Anticandidal activities of Brazilian seaweed extracts showed MIC at the range of 65–303 $\mu\text{g ml}^{-1}$ (Stein *et al.*, 2011). Ethanol extracts of *H. musciformis* demonstrated MIC at 8 $\mu\text{g ml}^{-1}$ against *C. albicans*. The MIC and MFC results of the present study were higher than these studies. Maybe the more screening is needed in order to detect the active biochemical substances in the crude extracts.

Correlation coefficient (R^2) value in this study implies that sample variations of 94.23% for growth inhibition zone are attributable to the independent variables. The adjusted determination coefficient also confirm the model significance. A high degree of precision and a good deal of reliability of the experimental values was evaluated by the value of coefficient of variation. The model must exhibits a good fit and checking the model adequacy is essential (Wang *et al.*, 2008). F-value for the lack of fit confirming the model validity. The results confirmed that the model is adequate for the prediction of experimental variables. The resulting maximum value of growth inhibition zone of 26.23 mm obtained at 91.7% desirability with the following concentrations of different seaweed extracts:

Gracilaria arquata extract (10 mg ml^{-1}), *Nizimudinia zanardini* extract (5 mg ml^{-1}), *Cystoceria indica* extract (4.5 mg ml^{-1}), *Padina australis* extract (2 mg ml^{-1}).

In the past years, combination therapies study by more than one active

ingredient more interested at pharma industries in compare to the search for specifically targeted drugs, for example, most Chinese drugs are mixtures of diverse herbal medicines (Qiu, 2007). Inside total extract of an herb, or between different herbs extracts, synergistic interactions could be seen (Williamson, 2001). This synergy may be the reason of isolating failed for single active compound from herbal drugs (Stermitz *et al.*, 2000). Maximum therapeutic efficacy with minimal side effects could be resulted in remedial treatment containing multiple drugs with related mechanisms (Wang *et al.*, 2008).

Among two agents by synergistic interaction, one of them enhanced the activity of the second one and they could act more effective in combination. An increasing of antimicrobial activity, better treatment at antimicrobial resistance, inhibition of resistance development, use less dosage of toxic agents, and enhanced bactericidal activity compared with monotherapy is the other improved efficacy of combination therapy (Harris and Coote, 2010).

Synergistic effects of antibacterial compounds is a new research category. The combination therapy of herbal extracts and antimicrobial agents can result in the inhibition of microbial pathogens, or it may happen because the combination is as effective as their individual therapeutic potential (Gibbons, 2004).

Based on our results, the combination of seaweed extracts had an additional inhibition effect on the growth of

Candida albicans, compared with individual extract usage. This could be a new finding, in anticandidal therapy. No literature found on the synergistic effects of marine algae extracts, but synergistic effects of catechins, antimycotics, and copper sulfate in the anticandidal therapy was reported (Anand and Rai, 2017). Also, a combination of menthol with itraconazole and nystatin has been showed the synergistic anticandidal activity (Sharifzadeh *et al.*, 2017). The synergistic effect of optimized seaweed extract compounds could be a novel category in the Candidiasis therapy.

In conclusion, the combined extracts of four different seaweeds are useful materials for *C. albicans* growth inhibition versus using this extract individually. The highest inhibition zone of candida growth was found based on the following concentrations: *G. arquata* extract (10 mg ml⁻¹), *N. zanardini* extract (5 mg ml⁻¹), *C. indica* extract (4.5 mg ml⁻¹), *P. australis* extract (2 mg ml⁻¹) which resulted in a growth inhibition zone of 26.23 mm for *C. albicans*.

Acknowledgments

The author would like to thank Dr. Ahmad Gharaei, Head of the Hamoon International Wetland Research Institute, for his invaluable help during various stages of this research.

References

- Anand, J. and Rai, N., 2017. Anticandidal synergistic activity of green tea catechins, antimycotics and copper sulphate as a mean of

- combinational drug therapy against candidiasis. *Journal de Mycologie Médicale*, 27(1), 33-45.
- Anaissie, E.J., 2008.** Diagnosis and therapy of fungal infection in patients with leukemia-new drugs and immunotherapy. *Best Practice and Research in Clinical Haematology*, 21(4), 683–690.
- Bansemir, A., Blume, M., Schroder, S. and Lindequist, U., 2006.** Screening of cultivated seaweeds for antibacterial activity against fish pathogenic bacteria. *Aquaculture*, 252(1), 79-84.
- Black, K.E. and Baden, L.R., 2007.** Fungal infections of the CNS: treatment strategies for the immunocompromised patient. *CNS Drugs*, 21(4), 293–318.
- Cannon, R.D., Lamping, E., Holmes, A.R., Niimi, K., Tanabe, K., Niimi, M. and Monk, B.C., 2007.** *Candida albicans* drug resistance – another way to cope with stress. *Microbiology*, 153(10), 3211-3217.
- Chew, Y.L., Lim, Y., Omar, M. and Khoo, K.S., 2008.** Antioxidant activity of three edible seaweeds from two areas in South East Asia. *LWT*, 41(6), 1067-1072.
- Chudzik, B., Tracz, I.B., Czernel, G., Fiolka, M.J., Borsuk, G. and Gagoś, M., 2013.** Amphotericin B–copper(II) complex as a potential agent with higher antifungal activity against *Candida albicans*. *European Journal of Pharmaceutical Sciences*, 49(5), 850–857.
- Duraipandiyan, V. and Ignacimuthu, S., 2011.** Antifungal activity of traditional medicinal plants from Tamil Nadu, India. *Asian Pacific Journal of Tropical Biomedicine*, 1(2), 204-215.
- Ertürk, Ö. and Tas, B., 2011.** Antibacterial and antifungal effects of some marine algae. *Kafkas Universitesi Veteriner Fakültesi Dergisi*, 17 (Suppl. A), S121–S124.
- Gibbons, S., 2004.** Anti-staphylococcal plant natural products. *Natural Product Reports*, 21(2), 263-77.
- Guedes, E.A.C., dos Santos Araújo, M.A., Souza, A.K.P., Souza, L.I.O., Barros, L.D., Albuquerque Maranhão, F.C. and Sant’Ana, A.E.G., 2012.** Antifungal activities of different extracts of marine macroalgae against dermatophytes and *Candida* species. *Mycopathologia*, 174(3), 223–232.
- Harris, M.R. and Coote, P.J., 2010.** Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of *Candida albicans* and *Candida glabrata* *in vitro*. *International Journal of Antimicrobial Agents*, 35(4), 347-356.
- Kumar, P., Senthamil Selvi, S. and Govindaraju, M., 2013.** Seaweed-mediated biosynthesis of silver nanoparticles using *Gracilaria corticata* for its antifungal activity against *Candida* spp. *Applied Nanoscience*, 3(6), 495–500.
- Kustos, I., Nyul, A., Lóránd, T., Kocsis, B. and Kilár, F., 2006.** Effect of antifungal agents on protein composition of *Candida albicans* studied by capillary electrophoresis and chip technology.

- Journal of Biochemical and Biophysical Methods*, 69(1-2), 57–65.
- Marr, K.A., Boeckh, M., Carter, R.A., Kim, H.W. and Corey, L., 2004.** Combination antifungal therapy for invasive aspergillosis. *Clinical Infection Disease*, 39(6), 797-802.
- Meunier, F. and Lukan, C., 2008.** The first European Conference on infections in Leukaemia-ECIL1: A current perspective. *European Journal of Cancer*, 44(15), 2112–2117.
- Mhadhebi, L., Chaieb, K. and Bouraoui, A., 2012.** Evaluation of antimicrobial activity of organic fractions of six marine algae from Tunisian Mediterranean coasts. *International Journal of Pharmacy and Pharmaceutical Science*, 4(1), 534–537.
- Mishra, N.N., Prasad, T., Sharma, N., Payasi, A., Prasad, R., Gupta, D.K. and Singh, R., 2007.** Pathogenicity and drug resistance in *Candida albicans* and other yeast species. *Acta Microbiologica Et Immunologica Hungarica*, 54(3), 201–235.
- Peres, N.T.A., Maranhão, F.C.A., Rossi, A. and Martinez-Rossi, N.M., 2010.** Dermatophytes: host pathogen interaction and antifungal resistance. *Anais Brasileiros Dermatologia*, 85(5), 657–667.
- Pyun, M.S. and Shin, S., 2006.** Antifungal effects of the volatile oils from *Allium* plants against *Trichophyton* species and synergism of the oils with ketaconazole. *Phytomedicine*, 13(6), 394-400.
- Qiu, J., 2007.** Back to the future for Chinese herbal medicines. *Nature Reviews Drug Discovery*, 6(7), 506–507.
- Rakholiya, K.D., Kaneria, M.J. and Chanda, S.V., 2013.** Medicinal plants as alternative sources of therapeutics against multidrug-resistant pathogenic microorganisms based on their antimicrobial potential and synergistic properties. In: Rai, M. & Kon, K. (eds.) *Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and Their Components*. Academic Press. pp. 165-179.
- Salvador, N., Gómez Garreta, A., Lavelli, L. and Ribera, M.A., 2007.** Antimicrobial activity of Iberian macroalgae. *Scientia Marina*, 71(1), 101-113.
- Sharifzadeh, A., Khosravi, A.R., Shokri, H. and Samadi Tari, P., 2017.** Synergistic anticandidal activity of menthol in combination with itraconazole and nystatin against clinical *Candida glabrata* and *Candida krusei* isolates. *Microbial Pathogenesis*, 107, 390-396.
- Shobier, A.H., Abdel Ghani S.A. and Barakat, K.M., 2016.** GC/MS spectroscopic approach and antifungal potential of bioactive extracts produced by marine macroalgae. *Egyptian Journal of Aquatic Research*, 42(3), 289–299.
- Silverman, R.B. and Holladay, 2014.** Drug resistance and drug synergism (chapter 7). *The Organic Chemistry*

- of Drug Design and Drug Action (Third Edition). Academic press. 517 P.
- Sobel, J.D., 2004.** Combination therapy for invasive mycoses: evaluation of past clinical trial designs. *Clinical Infection Disease*, 39(4), 224-227.
- Standards, N.C.F.C.L., 2002.** Reference method for broth dilution testing of yeasts. Approved standard, second edition, M27-A2. Wayne, Pa. pp. 1-13.
- Stein, E.M., Colepicolo, P., Afonso, F.A.K. and Fujii, M.T., 2011.** Screening for antifungal activities of extracts of the Brazilian seaweed genus *Laurencia* (Ceramiales, Rhodophyta). *Revista Brasileira de Farmacognosia*, 21(2), 290-295.
- Stermitz, F.R., Lorenz, P., Tawara, J.N., Zenewicz, L.A. and Lewis, K., 2000.** Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5-methoxyhydnocarpin, a multidrug pump inhibitor. *The Proceedings of the National Academy of Sciences of the United States of America*, 97(4), 1433-1437.
- Tuney, I., Cadirci, B.H., Unal, D. and Sukatar, A., 2006.** Antimicrobial activities of the extracts of marine algae from the coast of Urla (Izmir, Turkey). *Turkish Journal of Biology*, 30(3), 171-175.
- Ushimaru, P.I., Barbosa, L.N., Fernandes, A.A.H., Di Stasi, L.C. and Fernandes Ju'nior, A., 2012.** In vitro antibacterial activity of medicinal plant extracts against *Escherichia coli* strains from human clinical specimens and interactions with antimicrobial drugs. *Natural Products Research*, 26(16), 1553-1557.
- Wang, L., Zhou, G.B., Liu, P., Song, J.H., Liang, Y., Yan, X.J., Xu, F., Wang, B.S., Mao, J.H., Shen, Z.X., Chen, S.J. and Chen, Z., 2008.** Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. *The Proceedings of the National Academy of Sciences of the United States of America*, 105(12), 4826-4831.
- Williamson, E.M., 2001.** Synergy and other interactions in phytomedicines. *Phytomedicine*, 8(5), 401-409.
- Wright, G.D., 2007.** The antibiotic resistome: the nexus of chemical and genetic diversity. *Nature Reviews Microbiology*, 5(3), 175-186.
- Xu, J., Boyd, C.M., Livingston, E., Meyer, W., Madden, J.F. and Mitchell, T.G., 1999.** Species and Genotypic Diversities and Similarities of Pathogenic Yeasts Colonizing Women. *Journal of Clinical Microbiology*, 37(12), 3835-3843.
- Yuan, Y.V., Carrington, M.F. and Walsh, N.A., 2005.** Extracts from dulce (*Palmaria palmata*) are effective antioxidants and inhibitors of cell proliferation in vitro. *Food and Chemical Toxicology*, 43(7), 1073-1081.